메인의 폐암 임상 시험
폐암 관련 연구 12개가 메인 내 여러 지역에서 참여자를 모집하고 있습니다.
메인의 도시
공식 연구 텍스트(영어)
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Local Institution - 0127, Scarborough
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT07063745This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Maine Medical Center, Portland
- MaineHealth Cancer Care and Blood Disorders Scarborough, Scarborough
- MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06758401Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Maine Medical Center- Scarborough, Scarborough
- MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06498635Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Waldo Hospital, Belfast
- Lafayette Family Cancer Center-EMMC, Brewer
- 외 5개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT04267848Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
- Lafayette Family Cancer Center-EMMC, Brewer
피험자 모집 중3상
70세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT06096844A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- New England Cancer Specialists ( Site 0095), Westbrook
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT06312137Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Waldo Hospital, Belfast
- Lafayette Family Cancer Center-EMMC, Brewer
- 외 9개
피험자 모집 중관찰 연구건강한 지원자 환영
40세 ~ 75세 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT05334069Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Lafayette Family Cancer Center-EMMC, Brewer
피험자 모집 중2상
18 Minutes · 모든 성별 · 2026. 10. 9. 업데이트됨 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Waldo Hospital, Belfast
- Lafayette Family Cancer Center-EMMC, Brewer
- 외 6개
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 10. 9. 업데이트됨 · NCT06616584Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- MaineHealth Maine Medical Center - Portland, Portland
- MaineHealth Cancer Care Center of York County, Sanford
- MaineHealth Maine Medical Center- Scarborough, Scarborough
- 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT05624996Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Lafayette Family Cancer Center-EMMC, Brewer
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 6. 3. 업데이트됨 · NCT05642572SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Scarborough
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 10. 28. 업데이트됨 · NCT03452774ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.